Capricor Therapeutics (NASDAQ:CAPR) Announces Earnings Results, Beats Expectations By $0.15 EPS

Capricor Therapeutics (NASDAQ:CAPR) announced its earnings results on Wednesday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.15, Zacks reports. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%.

Capricor Therapeutics Trading Up 5.3 %

Shares of CAPR stock traded up $0.61 during trading hours on Wednesday, hitting $12.22. 1,027,458 shares of the company’s stock were exchanged, compared to its average volume of 1,364,117. The company has a market capitalization of $555.64 million, a PE ratio of -11.53 and a beta of 4.10. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40. The business’s 50 day simple moving average is $14.09 and its 200-day simple moving average is $14.51.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Monday. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.